How to buy Accelerate Diagnostics stock (AXDX)

Accelerate Diagnostics is a medical devices business based in the US. Accelerate Diagnostics shares (AXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.19 – a decrease of 9.16% over the previous week. Accelerate Diagnostics employs 134 staff and has a trailing 12-month revenue of around $12.2 million.

Our top picks for where to buy Accelerate Diagnostics stock

Buy Accelerate Diagnostics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Accelerate Diagnostics stock price (NASDAQ: AXDX)

Use our graph to track the performance of AXDX stocks over time.

Accelerate Diagnostics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$1.19
52-week range	$0.73 - $4.41
50-day moving average more info button	$1.73
200-day moving average more info button	$1.38
Wall St. target price	$1.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.59

Is it a good time to buy Accelerate Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Accelerate Diagnostics price performance over time

Historical closes compared with the close of $1.2 from 2024-12-18

1 week (2024-12-13)	-8.40%
1 month (2024-11-20)	-29.41%
3 months (2024-09-20)	-22.08%
6 months (2024-06-20)	-4.00%

1 year (2023-12-20)	-72.48%
2 years (2022-12-20)	-80.00%
3 years (2021-12-20)	48.1
5 years (2019-12-20)	170.5

Accelerate Diagnostics financials

Revenue TTM	$12.2 million
Gross profit TTM	$3.3 million
Return on assets TTM	-75.85%
Return on equity TTM	0%
Profit margin	0%
Book value	$-1.37
Market Capitalization more info button	$30.1 million

TTM: trailing 12 months

Accelerate Diagnostics share dividends

We're not expecting Accelerate Diagnostics to pay a dividend over the next 12 months.

Have Accelerate Diagnostics's shares ever split?

Accelerate Diagnostics's shares were split on a 1:10 basis on 11 July 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Accelerate Diagnostics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Accelerate Diagnostics shares which in turn could have impacted Accelerate Diagnostics's share price.

Accelerate Diagnostics share price volatility

Over the last 12 months, Accelerate Diagnostics's shares have ranged in value from as little as $0.73 up to $4.4117. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Accelerate Diagnostics's is 0.598. This would suggest that Accelerate Diagnostics's shares are less volatile than average (for this exchange).

Accelerate Diagnostics overview

Accelerate Diagnostics, Inc. , an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc.

Frequently asked questions

null
What percentage of Accelerate Diagnostics is owned by insiders or institutions?
Currently 40.605% of Accelerate Diagnostics shares are held by insiders and 17.452% by institutions. How many people work for Accelerate Diagnostics?
Latest data suggests 134 work at Accelerate Diagnostics. When does the fiscal year end for Accelerate Diagnostics?
Accelerate Diagnostics's fiscal year ends in December. Where is Accelerate Diagnostics based?
Accelerate Diagnostics's address is: 3950 South Country Club Road, Tucson, AZ, United States, 85714 What is Accelerate Diagnostics's ISIN number?
Accelerate Diagnostics's international securities identification number is: US00430H1023 What is Accelerate Diagnostics's CUSIP number?
Accelerate Diagnostics's Committee on Uniform Securities Identification Procedures number is: 004304200